TY - JOUR
T1 - Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism
AU - Ogawa, Akiko
AU - Watanabe, Satoshi
AU - Ozerova, Iuliia
AU - Tsai, Allen Yi Lun
AU - Kuchitsu, Yoshihiko
AU - Chong, Harrison Byron
AU - Kawakami, Tomoyoshi
AU - Fuse, Jirio
AU - Han, Wei
AU - Kudo, Ryuhei
AU - Naito, Tomoki
AU - Sato, Kota
AU - Nakazawa, Toru
AU - Saheki, Yasunori
AU - Hirayama, Akiyoshi
AU - Stadler, Peter F.
AU - Arisawa, Mieko
AU - Araki, Kimi
AU - Bar-Peled, Liron
AU - Taguchi, Tomohiko
AU - Sawa, Shinichiro
AU - Inaba, Kenji
AU - Wei, Fan Yan
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025
Y1 - 2025
N2 - RNA contains diverse post-transcriptional modifications, and its catabolic breakdown yields numerous modified nucleosides requiring correct processing, but the mechanisms remain unknown. Here, we demonstrate that three RNA-derived modified adenosines, N6-methyladenosine (m6A), N6,N6-dimethyladenosine (m6,6A), and N6-isopentenyladenosine (i6A), are sequentially metabolized into inosine monophosphate (IMP) to mitigate their intrinsic cytotoxicity. After phosphorylation by adenosine kinase (ADK), they undergo deamination by adenosine deaminase-like (ADAL). In Adal knockout mice, N6-modified adenosine monophosphates (AMPs) accumulate and allosterically inhibit AMP-activated protein kinase (AMPK), dysregulating glucose metabolism. Furthermore, ADK deficiency, linked to human inherited disorders of purine metabolism, elevates levels of the three modified adenosines, resulting in early lethality in mice. Mechanistically, excessive m6A, m6,6A, and i6A impair lysosomal function by interfering with lysosomal membrane proteins, thereby disrupting lipid metabolism and causing cellular toxicity. Through this nucleotide metabolism pathway and mechanism, cells detoxify modified adenosines, linking modified RNA metabolism to human disease.
AB - RNA contains diverse post-transcriptional modifications, and its catabolic breakdown yields numerous modified nucleosides requiring correct processing, but the mechanisms remain unknown. Here, we demonstrate that three RNA-derived modified adenosines, N6-methyladenosine (m6A), N6,N6-dimethyladenosine (m6,6A), and N6-isopentenyladenosine (i6A), are sequentially metabolized into inosine monophosphate (IMP) to mitigate their intrinsic cytotoxicity. After phosphorylation by adenosine kinase (ADK), they undergo deamination by adenosine deaminase-like (ADAL). In Adal knockout mice, N6-modified adenosine monophosphates (AMPs) accumulate and allosterically inhibit AMP-activated protein kinase (AMPK), dysregulating glucose metabolism. Furthermore, ADK deficiency, linked to human inherited disorders of purine metabolism, elevates levels of the three modified adenosines, resulting in early lethality in mice. Mechanistically, excessive m6A, m6,6A, and i6A impair lysosomal function by interfering with lysosomal membrane proteins, thereby disrupting lipid metabolism and causing cellular toxicity. Through this nucleotide metabolism pathway and mechanism, cells detoxify modified adenosines, linking modified RNA metabolism to human disease.
KW - ADAL
KW - Adenosine deaminase-like
KW - Adenosine kinase
KW - ADK
KW - AMP-activated protein kinase
KW - AMPK
KW - Lipid metabolism
KW - Lysosome
KW - mA
KW - Modified RNA metabolism
KW - Purine metabolism
KW - RNA modification
UR - http://www.scopus.com/inward/record.url?scp=105013631230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105013631230&partnerID=8YFLogxK
U2 - 10.1016/j.cell.2025.07.041
DO - 10.1016/j.cell.2025.07.041
M3 - Article
AN - SCOPUS:105013631230
SN - 0092-8674
JO - Cell
JF - Cell
ER -